A study investigates the effects of GLP-1 and GIP receptor agonism on human myotubes, finding no direct influence on muscle atrophy or myogenesis, suggesting indirect mechanisms behind lean mass loss.
This study evaluates the efficacy of retatrutide, a triple hormone receptor agonist, in treating obesity through a randomized controlled trial involving adults without diabetes.
This review examines the relationship between GLP-1-derived therapies and the risk of sarcopenia, highlighting mixed results and the need for further research.
A study investigates the effects of whey protein on muscle damage, liver stress, and inflammation in trained athletes, revealing potential benefits for recovery and adaptation.
This systematic review and meta-analysis evaluates body composition changes during GLP-1-based therapy, highlighting effects on adiposity and muscle metrics.
This review explores emerging pharmacotherapies for obesity, highlighting their potential beyond weight loss and their impact on obesity-related complications.
This review discusses the evolution of GLP-1 from its discovery to its role in diabetes and obesity therapies, highlighting its physiological effects and therapeutic potential.
This study evaluates the effects of retatrutide on lipid and metabolite profiles in individuals with obesity, with or without type 2 diabetes, revealing significant metabolic changes.
A 12-month multidisciplinary obesity management program including semaglutide shows significant improvements in gait speed among Japanese adults with musculoskeletal disorders.
A double-blind randomized controlled trial investigates the effects of 7-day creatine monohydrate loading on breath-hold exercise performance in trained divers, revealing significant performance enhancements.
